Research and Markets(http://www.researchandmarkets.com/research/57c330/oman_pharmaceutica) has announced the addition of the "Oman Pharmaceuticals and Healthcare Report Q4 2009" report to their offering.
This Oman Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Oman pharmaceuticals and healthcare industry
In the Q409 Business Environment Ranking (BER) matrix for Middle East and Africa (MEA), Oman is placed seventh, having improved its position by three places in relation to the previous quarter. However, as its score is unchanged, the shift can be explained as a result of the worsening of the scores awarded to other markets surveyed by BMI. Globally, Oman ranks 44th out of the total of 71 markets profiled, with its small population and strict price controls continuing to represent major barriers to investment in the market.
Nevertheless, Oman does offer certain advantages over larger - but less developed - markets in the MEA region. Its preference for branded products, combined with a low-cost manufacturing base and an improving intellectual property (IP) environment will conspire to increase the value of its market at retail prices from OMR44mn (US$117mn) in 2008 to OMR60mn (US$157mn) by 2013. The compound annual growth rate (CAGR) of the pharmaceutical expenditure is penned in at a steady yet unspectacular 6.07% in both US dollar and local currency terms, although the need for cost containment, especially given current economic turbulence, will result in the falling market share of patented products.